Ampliphi Biosciences Corp (APHB) Sees Significant Decrease in Short Interest

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw a large decrease in short interest in the month of December. As of December 29th, there was short interest totalling 851,483 shares, a decrease of 4.5% from the December 15th total of 891,694 shares. Currently, 9.1% of the company’s shares are sold short. Based on an average daily volume of 104,314 shares, the days-to-cover ratio is presently 8.2 days.

Shares of Ampliphi Biosciences (APHB) opened at $1.12 on Thursday. The company has a market capitalization of $13.01, a price-to-earnings ratio of -0.11 and a beta of 2.93. Ampliphi Biosciences has a twelve month low of $0.67 and a twelve month high of $6.80.

Separately, HC Wainwright set a $5.00 price target on Ampliphi Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th.

TRADEMARK VIOLATION WARNING: “Ampliphi Biosciences Corp (APHB) Sees Significant Decrease in Short Interest” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/11/ampliphi-biosciences-corp-aphb-sees-significant-decrease-in-short-interest.html.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply